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Effective tight glycemic control (TGC) can improve outcomes in critical care patients, but it 
is difficult to achieve consistently. Insulin sensitivity defines the metabolic balance between 
insulin concentration and insulin-mediated glucose disposal. Hence, variability of insulin 
sensitivity can cause variable glycemia. This study quantifies and compares the daily 
evolution of insulin sensitivity level and variability for critical care patients receiving TGC. 
Methods 
This is a retrospective analysis of data from the SPRINT TGC study involving patients 
admitted to a mixed medical-surgical ICU between August 2005 and May 2007. Only 
patients who commenced TGC within 12 hours of ICU admission and spent at least 24 hours 
on the SPRINT protocol were included (N = 164). Model-based insulin sensitivity (SI) was 
identified each hour. Absolute level and hour-to-hour percent changes in SI were assessed on 
cohort and per-patient bases. Levels and variability of SI were compared over time on 24-
hour and 6-hour timescales for the first 4 days of ICU stay. 
Results 
Cohort and per-patient median SI levels increased by 34% and 33% (p < 0.001) between days 
1 and 2 of ICU stay. Concomitantly, cohort and per-patient SI variability decreased by 32% 
and 36% (p < 0.001). For 72% of the cohort, median SI on day 2 was higher than on day 1. 
The day 1–2 results are the only clear, statistically significant trends across both analyses. 
Analysis of the first 24 hours using 6-hour blocks of SI data showed that most of the 
improvement in insulin sensitivity level and variability seen between days 1 and 2 occurred 
during the first 12–18 hours of day 1. 
Conclusions 
Critically ill patients have significantly lower and more variable insulin sensitivity on day 1 
than later in their ICU stay and particularly during the first 12 hours. This rapid improvement 
is likely due to the decline of counter-regulatory hormones as the acute phase of critical 
illness progresses. Clinically, these results suggest that while using TGC protocols with 
patients during their first few days of ICU stay, extra care should be afforded. Increased 
measurement frequency, higher target glycemic bands, conservative insulin dosing, and 
modulation of carbohydrate nutrition should be considered to minimize safely the outcome 
glycemic variability and reduce the risk of hypoglycemia. 
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Safe, effective tight glycemic control (TGC) of critically ill patients can improve outcomes 
[1-4], but it is difficult to achieve consistently [5-7]. Glycemic level and variability in TGC 
are a function of variability in insulin sensitivity, potentially resulting from the level and 
evolution of the stress response [8], and are independently associated with mortality [9-12]. 
Insulin sensitivity defines the metabolic balance between insulin concentration and glucose 
disposal. Insulin-mediated glucose disposal is a dominant pathway to reduce and control 
glycemia in critically ill patients. For a fixed insulin concentration, a given percentage change 
of insulin sensitivity results in a proportional change to glucose disposal and thus glycemic 
level, all else equal. 
Understanding the variability of insulin sensitivity, over hours and days, is important for 
safely and effectively managing glycemic levels with exogenous insulin. Several patient- and 
treatment-related factors influence insulin sensitivity. Some of the influential and predictable 
factors (drug therapies and existing patient conditions) are taken into account when 
developing therapeutic algorithms for insulin treatment. 
The objective of this study was to examine the evolution of insulin sensitivity level and 
variability over the first 4 days of intensive care unit (ICU) stay using data from the SPRINT 
TGC study [1]. Analyses were performed on two separate timescales, using 24-hour and 6-
hour blocks of data. The impact of this insulin sensitivity evolution on glycemia in the 




This study is a retrospective analysis of patient data (N = 164 patients, 12,067 hours) from the 
SPRINT clinical practise change in the Christchurch Hospital ICU [1]. All patients admitted 
between August 2005 and May 2007 were included where the SPRINT TGC protocol was 
commenced within 12 hours of ICU admission and continued for at least 24 hours. All 
patients were treated per protocol, with no specific exclusions. Table 1 presents a summary of 
cohort details. 
Table 1.  Summary details of the study subjects 
N 164 
Age (yr) 65 [56–74] 
Gender (M/F) 102/62 
APACHE II score 19 [16–25] 
APACHE II ROD (%) 32 [17–52] 
Operative/nonoperative 66/98 
Hospital mortality 25% 
ICU mortality 18% 
ICU length of stay (hr) 142 [70–308] 
Diabetic history: type I/type II 10/22 
Data are presented as median [interquartile range] where appropriate 
The Christchurch Hospital ICU is a 15-bed, closed, mixed medical-surgical unit led by 
intensive care specialists in a tertiary affiliated teaching hospital. Glycemic control data were 
collected from handwritten daily ICU charts and entered into a spreadsheet database. The 
Upper South Regional Ethics Committee, New Zealand, granted approval for the audit, 
analysis, and publication of this data. 
The SPRINT protocol 
The SPRINT protocol (SPecialised Relative Insulin Nutrition Tables) is a simple, lookup-
table system derived from a model-based controller that modulates both insulin and 
nutritional inputs. The protocol titrates insulin doses and nutrition rates to estimated patient-
specific insulin sensitivity for tight glycemic control in the range 4.0–6.1 mmol/L BG range 
[1, 13, 14]. SPRINT has been the standard of care in the Christchurch ICU since August 
2005. The requirement for the patients in this study to be on the SPRINT protocol ensured 
that they had regular and accurate records of blood glucose levels, insulin administered, and 
nutrition given. 
The entry criterion for the SPRINT protocol was two BG measurements >8 mmol/L during 
normal patient monitoring, or at the discretion of the clinician. Once on the protocol, BG was 
measured 1- to 2-hourly, with a median measurement interval for this cohort of 1.5 hours. BG 
measurements were taken by nursing staff using the Arkray Super-Glucocard II glucometer 
(Arkray Inc., Japan). Blood samples tested were typically arterial, although when an arterial 
line was not present, capillary blood was used. Additional File 1 contains a more detailed 
description of SPRINT and specific, unique differences to other protocols. 
Model-based insulin sensitivity 
Model-based methods provide a means of determining physiological parameters that either 
cannot be measured directly or are impractical to measure with the required frequency. In this 
study, model-based insulin sensitivity (SI) was identified using an integral method [15] with a 
validated glucose-insulin system model developed for critical care patients [16, 17]. The 
glucose-insulin system model is illustrated schematically in Figure 1 and presented in greater 
detail in Additional File 2. 
 
Figure 1.  Schematic illustration of the glucose-insulin system model used in this 
analysis. 
The SI parameter represents “whole-body” insulin sensitivity. The parameter defines the 
glycemic response to exogenous insulin and nutrition, capturing the relative net effect of 
 
 
altered endogenous glucose production, peripheral and hepatic insulin mediated glucose 
uptake, and endogenous insulin secretion. However, this time-varying insulin sensitivity 
parameter has been shown to correlate very well (r > 0.9) with the “gold standard” 
euglycemic clamp [17] and has been used to guide model-based TGC in several studies [18-
20]. 
A value of SI was identified every hour [15] for each patient using clinical data and the model 
implemented in MATLAB (2011a, Mathworks, Natick, MA). When the BG measurement 
interval was greater than 1 hour, linearly interpolated values were used for identification. 
Variability of insulin sensitivity was calculated as the hour-to-hour percentage change in SI 
(Δ%SI), defined below: 





+ −Δ = ×  
 
Use of percentage change in SI, rather than absolute change, normalizes the metric so that 
patients with very different absolute levels of SI can be compared fairly. Equally, for a fixed 
insulin concentration, a given percentage change in insulin sensitivity results in a 
proportional change to glucose disposal and thus glycemic level, all else equal. 
Analyses 
SI level and variability are analyzed on overall cohort and per-patient bases using two 
separate timescales. The evolution of SI over the first 4 days of ICU stay is analyzed in 24-
hour blocks. Bagshaw [12] reported an association between hypoglycemia and variability 
during the first 24 hours of ICU stay and mortality. We therefore also analyzed the acute 
evolution of SI over the first day using 6-hour blocks. 
Cohort analysis looks at the hourly values of SI and variability for the entire cohort grouped 
together and shows trends in the overall group behavior. To quantify per-patient variability, 
the interquartile range (IQR: 25th–75th percentile) of Δ%SI is examined for each patient 
within each timescale. This metric captures the width of the variability distribution for each 
patient. Per-patient SI level is defined by the median value within each timescale. 
The analyses are linked to time on the SPRINT protocol, rather than time in the ICU, to 
ensure sufficient insulin and nutrition data to accurately identify SI hourly [15]. Hence, day 1 
comprises the first 24 hours of SPRINT. However, because patients were included only if 
they commenced SPRINT within 12 hours of ICU admission, a minimum of half of the day 1 
results for each patient occur during their first 24 hours in the ICU. The median delay 
between admission and commencement of SPRINT for this cohort was 1.9 hours and 81% of 
the cohort was on SPRINT within 6 hours. When a patient was taken off the SPRINT 
protocol, their SI profile for the last day was included in the analysis only if it contained 6 
hours or more of data. 
SI levels and variability are non-Gaussian and thus compared using cumulative distribution 
functions (CDFs) and nonparametric statistics. Distributed data are generally compared using 
the Wilcoxon rank-sum test (Mann-Whitney U test), except for SI variability results. SI 
variability is compared using the Kolmogorov-Smirnov test, because it has more power to 
detect differences in the shape of distributions than the rank-sum test when median values are 




Twenty-four hour analyses 
Insulin sensitivity level 
Figure 2 presents the cumulative distribution functions (CDFs) of hourly SI for each day by 
cohort (left panel) and median daily SI per-patient (right panel). Table 2 presents the increase 
in median insulin sensitivity and associated p values between successive days. Both per-
patient and cohort analyses suggest that insulin sensitivity levels start low, but increase over 
time in the ICU. There is a particularly significant increase between days 1 and 2 (p < 0.001). 
On subsequent days the increase continues but to a lesser degree. Per-patient comparisons 
between days 2, 3, and 4 are not statistically significant. 
 
Figure 2.  Insulin sensitivity level distributions by cohort (left) and per-patient median 
(right) using 24-hr blocks of data 
















































Table 2.  Increasing cohort and per-patient median insulin sensitivity over time (24-hr 
blocks) 
Level analysis Cohort analysis Per-patient analysis 
% Increase at median p value % Increase at median p value 
Days 1-2 34 <0.0001 33 0.0004 
Days 2-3 16 <0.0001 21 0.2559 
Days 3-4 6 0.0013 4 0.6306 
P values calculated using Wilcoxon rank-sum test. 
The results of Figure 2 and Table 2 are further reflected in Table 3, which shows that daily 
median insulin sensitivity increases for a large proportion of the cohort between days 1 and 2 
with lesser proportions on subsequent days. Table 3 is a matrix where the value in a cell 
represents the proportion of patients for whom daily median insulin sensitivity is greater on 
the day of the associated column than the day of the associated row. For example, 72% of 
patients show an increase in median SI between days 1 and 2, and 54% when comparing days 
2 and 3. 
Table 3.  Proportion of patients for whom median insulin sensitivity increases between 
the days indicated in the rows and columns 
 Day 2 Day 3 Day 4 
Day 1 0.72 0.74 0.71 
Day 2  0.54 0.64 
Day 3   0.53 
 
Insulin sensitivity variability 
SI variability decreases over time in the ICU, parallel to increases in absolute SI level. Figure 
3 and Table 4 present the CDFs and tabulated results for cohort and per-patient analyses of 
the hour-to-hour percentage changes in SI (Δ%SI). The cohort aggregate distributions of 
Δ%SI by day are shown in the left panel of Figure 3. The right panel presents the CDFs for 
the per-patient IQRs by day. 
 
Figure 3.  Insulin sensitivity variability distributions by cohort (hour-to-hour 
percentage change) and per-patient interquartile-range using 24 hr blocks of data 
 
As with insulin sensitivity level, the largest increase in SI variability is between days 1 and 2. 
The decrease between days 2, 3, and 4 is statistically significant for both cohort and per-
patient analyses, but the change is much less than over the first day and may not be clinically 
significant. 
 











Cohort variability analysis 





















Per-patient variability analysis 










Table 4.  Reductions in the interquartile range (IQR) and median per-patient range of 
hour-to-hour percentage insulin sensitivity change over time 
Variability analysis Cohort analysis Per-patient analysis 
% Reduction of IQR p-value % Decrease at median p value 
Days 1-2 32 <0.0001 36 <0.0001 
Days 2-3 20 0.0028 18 0.0091 
Days 3-4 14 0.0269 17 0.0369 
P values calculated using Kolmogorov-Smirnov test for cohort comparisons and Wilcoxon 
rank-sum test for per-patient comparisons. 
Six-hour analyses 
Insulin sensitivity level 
Figure 4 presents the distributions of cohort and per-patient insulin sensitivity over the first 
24 hours in 6-hour blocks. Also shown for comparison is the day 2 distribution from Figure 1 
(labeled 24–28 hours). It is evident that the insulin sensitivity level increases over the first 
day up to the level of the second day. Hence, the differences between day 1 and 2 seen in 
Figure 2 are a function of the low, but increasing, insulin sensitivity during the first 12–18 
hours. 
Table 5 lists the differences in median insulin sensitivity levels from the distributions shown 
in Figure 4. The increases in SI during the first 18 hours are large and statistically significant. 
Subsequent increases are unlikely to be clinically significant at less than 10%. Of particular 
interest is the comparison between 18–24 hours and day 2, which indicates that by 18 hours, 
the rapid increase in SI is largely complete. 
 Figure 4.  Insulin sensitivity level distributions by cohort (left) and per-patient median 
(right) using 6-hr blocks of data. 
Table 5.  Increasing cohort and per-patient median insulin sensitivity over time (6-hr 
blocks) 
Level analysis Cohort analysis Per-patient analysis 
% Increase at 
median 
p value % Increase at 
median 
p value 
Block 1–2 (0–6 vs. 6-12 hr) 42 <0.0001 40 0.0007 
Block 2–3 (6–12 vs. 12-18 hr) 28 <0.0001 26 0.0123 
Block 3–4 (12–18 vs. 18-24 
hr) 
1 0.0335 3 0.4829 
Block 4–5 (18–24 vs. 24–48 
hr) 
9 0.0452 7 0.3776 
P values calculated using Wilcoxon rank-sum test. 


















































Table 6 shows that during the first 18 hours, a large proportion of the patients have an 
increase of insulin sensitivity using the 6-hour timescale. After 18 hours, the proportion of 
patients with increasing SI is similar to that seen between days 2, 3, and 4 (Table 3) at slightly 
more than 50%. 
Table 6.  Proportion of patients for whom median insulin sensitivity increases between 
the blocks indicated in the rows and columns 
 6–12 hr 12–18 hr 18–24 hr 24–48 hr 
0–6 hr 0.74 0.78 0.77 0.79 
6–12 hr  0.76 0.7 0.72 
12–18 hr   0.55 0.64 
18–24 hr    0.58 
 
Insulin sensitivity variability 
As with absolute SI level, the majority of the decrease in SI variability occurred during the 
first 18 hours. Figure 5 shows the CDFs of the cohort and per-patient variability metrics. 
Table 7 shows that only the differences between 0–6 hours and 6–12 hours are statistically 
significant at the 5% level. The 6–12 vs. 12–18-hour comparison is close to statistical 
significance, with p < 0.07 for both cohort and per-patient analyses. 
 Figure 5.  Insulin sensitivity variability distributions by cohort (hour-to-hour 
percentage change) and per-patient interquartile-range using 6-hr blocks of data. 
Table 7.  Reductions of the interquartile range (IQR) and median per-patient range of 
hour-to-hour percentage insulin sensitivity change over time 
Variability analysis Cohort analysis Per-patient analysis 
% Reduction of 
IQR 
p value % Decrease at 
median 
p value 
Block 1–2 (0–6 vs. 6-12 hr) 40 0.0017 36 <0.0001 
Block 2–3 (6–12 vs. 12-18 hr) 24 0.0628 28 0.0673 
Block 3–4 (12–18 vs. 18-24 
hr) 
0 0.0931 9 0.1032 
Block 4–5 (18–24 vs. 24-48 
hr) 
18 0.1682 14 0.1075 
P values calculated using Kolmogorov-Smirnov test for cohort comparisons and Wilcoxon 
rank-sum test for per-patient comparisons. 











Cohort variability analysis 






















Per-patient variability analysis 












Insulin sensitivity variability 
Both cohort and per-patient results suggest that critically ill patients have significantly lower 
and more variable insulin sensitivity on day 1 than later in their ICU stay. Further analysis 
shows that this day 1 result is primarily influenced by the first 12–18 hours of ICU stay. Over 
this time, rapid improvements in insulin sensitivity level and variability occur so that there is 
no statistically significant difference between 18–24 hours and day 2. From day 2 onwards, 
changes in SI level and variability are not as large and of limited clinical and statistical 
significance. 
Within the analyses, there are some differences in significance between cohort and per-
patient results for comparisons after day 2. The overall findings noted in the preceding 
paragraph are the only clear, consistent trends across both analyses. 
The counter-regulatory hormones: cortisol, glucagon, the catecholamines, as well as growth 
hormone are significantly elevated almost immediately after critical-insult, but decline 
rapidly over the first 12–48 hours [21-24]. These hormones are known to cause increased 
hepatic glucose production, inhibition of insulin release, and peripheral insulin resistance 
[22], all of which cause a decrease in the model-based SI metric used in this study. Hence, the 
low but rapidly increasing insulin sensitivity seen during the first 12–18 hours of ICU stay is 
likely due to the acute counter-regulatory response to critical illness. 
Time in this study was referenced from the commencement of SPRINT, rather than ICU 
admission. However, the difference between admission time and commencing SPRINT was 
generally very short, with a median delay for this cohort of 1.9 hours. Within 6 hours of 
admission, 81% of the cohort had commenced SPRINT. Hence, these results are applicable to 
the first few hours and days of ICU stay. 
The insulin sensitivity parameter 
The model-based parameter used in this study represents a whole-body insulin sensitivity 
capturing overall metabolic response to exogenous insulin. SI captures the relative net effect 
of altered hepatic glucose production, peripheral and hepatic insulin-mediated glucose 
uptake, and endogenous insulin secretion. All of these effects are altered significantly in 
critical illness due to the stress response [25-27]. Hence, the metabolic balance that this 
parameter represents is an important consideration in TGC, because it determines a body’s 
glycemic response to exogenous insulin and nutrition. 
As an identified parameter, SI contains unmodeled physiological effects and measurement 
device noise. However, Lotz et al. [17] indicated that this form of insulin sensitivity 
correlated very well (r > 0.9) with the “gold standard” euglycemic clamp and its change in a 
lifestyle intervention study on 73 normoglycemic healthy and obese subjects (146 clamp 
procedures before/after intervention). In the critical care setting, a similar version of the 
model and SI parameter has been cross-validated against independent, matched patient data 
from a single center of the Glucontrol randomized, clinical trial [28]. 
The analytic inaccuracy of bedside glucometers or any other sensor used to gather BG 
measurements influence individual values of SI. However, this study examines distributions 
of SI consisting of thousands of values identified from a wide range of BG values, thus both 
the random and bias components of error cancel out within each distribution. This effect was 
confirmed by Monte Carlo analysis (results not shown) using an error model for the 
glucometer derived from data supplied by the manufacturer [29]. 
Implications for tight glycemic control 
With low and variable insulin sensitivity, glycemic levels may appear unresponsive and/or 
difficult to control effectively with exogenous insulin. This situation may provoke larger 
insulin doses from many protocols that have no explicit upper limits on insulin dose [6, 30-
32]. High levels of circulating insulin coupled with the observed variability in insulin 
sensitivity result in increased glycemic variability and an increased risk of hypoglycemia 
during the first 24 hours of ICU stay. 
Not only does glycemic variability pose a risk through hypoglycemia, it also is detrimental in 
its own right. Several studies [9-11, 33] have shown that glycemic variability is 
independently associated with mortality in critically ill patients. More specifically, Bagshaw 
[12] showed that hypoglycemia and variability within the first 24 hours of ICU stay are each 
associated with increased mortality. In vitro, high glycemic variability was shown to increase 
oxidative stress [34] and apoptosis [35], thereby suggesting a rationale to explain the clinical 
association with poor outcome. 
Evidence from other studies [10, 12] indicates an association between hypoglycemia, 
glycemic variability, and mortality. However, the question remains: Is low and variable 
glycemia the cause of increased morbidity and mortality? Or is it just a symptom in very ill 
patients? Until this question can be answered conclusively, it is perhaps best to formulate 
TGC protocols not to exacerbate the situation, which requires the ability to differentiate more 
and less metabolically variable patients. 
Another significant finding in this study is the range of variability seen across patients, as 
well as over time (Figures 3 and 5). Less variable patients, if identified, may be treated more 
aggressively with insulin without compromising glycemic variability. Hence, model-based 
methods have been mooted as a means of better managing this inter- and intra-patient 
variability [30, 36]. 
Limitations 
Only patients on the SPRINT TGC protocol were considered for this analysis as they had 
sufficient data density to identify SI hourly. Patients were put on the SPRINT protocol 
because they were hyperglycemic and thus were likely to be biased towards lower insulin 
sensitivity compared with other ICU patients. However, in the context of investigating the 
implications of SI variability on TGC, this cohort is appropriate. 
Another limitation is the use of a model-based insulin sensitivity parameter, as it is not 
measured directly and may be influenced by modelling errors or un-modelled effects. As an 
identified parameter, SI contains unmodeled physiological effects and measurement device 
noise. However, as noted previously, this form of SI has been shown to correlate very well 
with the “gold standard” euglycemic clamp [17, 37] and has been shown to be an independent 
marker of metabolic condition [28]. Finally, this method of analysis is robust to BG sensor 
error. 
A further limitation is the relatively small cohort size available for analysis. The demands of 
manually transcribing written clinical data into electronic form and the specific inclusion 
criteria have restricted the number of patients for whom complete glycemic control data are 
currently available for analysis. The size of this cohort has precluded subgroup analyses, such 
as diabetic and cardiovascular surgery patients, because these subgroups only contain 20–40 
patients. With relatively few patients, the subgroup analyses fail to demonstrate statistical 
significance, despite effect sizes and trends very similar to that seen in this overall analysis. 
Thus, these comparisons will be completed in the future, when more patient data become 
available. 
The findings of this study should be equally valid in other ICUs where attention to TGC and 
blood glucose measurement frequency may be a lower priority. Although the data density 
might not be present to allow such units to explicitly identify SI hourly, these results indicate 
that patients will still have lower and more variable insulin sensitivity on day 1 than later in 
their ICU stay. Thus, suggestions of higher glycemic targets, conservative insulin dosing, and 
modulation of carbohydrate nutrition are especially pertinent. 
Without the ability to identify patient-specific metabolic states, a protocol should be less 
aggressive over the first few days, and particularly the first 24 hours, to minimize variability. 
It may be important for protocols to consider higher glycemic targets on the first days of ICU 
stay (compared with later days) to ensure safety. Perhaps a glycemic target similar to the 
current guidelines of 7.8-11 mmol/L [38-40] is most appropriate for the first 24 hours with 
the target range, reducing over days 2 and 3 to more normoglycemic levels as SI level and 
variability improve. 
Greater blood glucose measurement frequency and conservative insulin dosing can mitigate 
the impact of SI variability on risk [41] and also should be considered for the first few days of 
stay. Modulation of carbohydrate nutrition, within limits [42], can reduce the need for 




The results of this study indicate that critically ill patients have significantly lower and more 
variable insulin sensitivity on day 1 than later in their ICU stay, particularly during the first 
12–18 hours. This effect is likely due to the acute counter-regulatory response to critical 
illness. Greater variability with lower SI early in a patient’s stay greatly increases the insulin 
required, potential glucose flux due to variation in SI, and thus the risk of greater glycemic 
variability and hypoglycemia. Both glycemic variability and hypoglycemia have been 
associated with poor outcomes in the ICU. 
Clinically, these results suggest that TGC patients require greater care over the first few days 
of ICU stay to minimize safely the outcome glycemic variability. It may be important for 
protocols to consider higher glycemic targets on the first days of ICU stay to ensure safety. 
Equally, greater measurement frequency, conservative insulin dosing, and modulation of 
carbohydrate nutrition can mitigate the impact of variability on risk and should be considered 
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